These data support the hypothesis that IFN elicits CML-specific CM CTL that may contribute to continuous CCR after IFN withdrawal and suggest a role for T cell immune therapy with or without tyrosine kinase inhibitors as a strategy to prolong CR in CML. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.